Drug Type Radiolabeled antibody, Diagnostic radiopharmaceuticals |
Synonyms 64Cu-DOTA-Rituximab, [64Cu]DOTA-rituximab, Cu-64 Rituximab + [1] |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Start Date10 Jan 2022 |
Sponsor / Collaborator |
Start Date13 Oct 2017 |
Sponsor / Collaborator- |
Start Date20 May 2015 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Phase 1 | - | - |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |